The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Prevention of Viral Hepatitis and Vaccination

바이러스간염의 예방과 예방접종

  • Cho, Yoo-Kyung (Department of Internal Medicine, Jeju National University School of Medicine) ;
  • Song, Byung-Cheol (Department of Internal Medicine, Jeju National University School of Medicine)
  • 조유경 (제주대학교 의학전문대학원 내과학교실) ;
  • 송병철 (제주대학교 의학전문대학원 내과학교실)
  • Published : 2012.02.01
⟨ Previous Next ⟩

Abstract

Hepatitis viruses are most important cause of acute and chronic hepatitis. In past, hepatitis B virus was one of the major causes of acute hepatitis. Recently, around 60-70% of acute hepatitis is attributed to hepatitis A virus infection. In this article, we will discuss the route of hepatitis virus infection, how to prevent transmission of viral hepatitis and who should be immunized to each hepatitis viruses.

Keywords

References

  1. Kang HM, Jeong SH, Kim JW,et al. Recent etiology and clinical features of acute viral hepatitis in a single center of Korea. Korean J Hepatol 2007;13:495-502. https://doi.org/10.3350/kjhep.2007.13.4.495
  2. Jeong SH. Current status and vaccine indication for hepatitis A virus infection in Korea. Korean J Gastroenterol 2008; 51:331-337.
  3. KCDC. National Immunization program [Internet]. Osong: Korea Centers for Disease Control and Prevention, c2011 [cited 2011 Dec 19]. Available from: http://nip.cdc.go.kr/ reference.do?service=getGuideView&strNum=3& GUISEQNUM= 26&SEARCHTYPE=&SEARCHWARD=.
  4. Lee D, Cho YA, Park Y, et al. Hepatitis a in Korea: epidemiological shift and call for vaccine strategy. Intervirology 2008;51:70-74.
  5. Lee A, Lim HS, Nam CM, Song SM, Yoon HR, Lee KR. An epidemiological analysis of hepatitis A virus serologic markers during the recent four years in Korea. Korean J Lab Med 2009;29:563-569. https://doi.org/10.3343/kjlm.2009.29.6.563
  6. Fiore AE, Wasley A, Bell BP. Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-7):1-23.
  7. Rezende G, Roque-Afonso AM, Samuel D, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003;38:613-618.
  8. McCaustland KA, Bond WW, Bradley DW, Ebert JW, Maynard JE. Survival of hepatitis A virus in feces after drying and storage for 1 month. J Clin Microbiol 1982; 16:957-958.
  9. Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med 2004;350:476-481. https://doi.org/10.1056/NEJMcp031540
  10. Van Damme P, Mathei C, Thoelen S, Meheus A, Safary A, Andre FE. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994;44:435-441. https://doi.org/10.1002/jmv.1890440422
  11. Victor J, Knudsen JD, Nielsen LP, et al. Hepatitis A vaccine: a new convenient single-dose schedule with booster when long-term immunization is warranted. Vaccine 1994;12:1327-1329 https://doi.org/10.1016/S0264-410X(94)80028-X
  12. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003;362:1065-1071. https://doi.org/10.1016/S0140-6736(03)14418-2
  13. Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007;119:e12-e21. https://doi.org/10.1542/peds.2006-1573
  14. Kang JH, Kim HB, Sohn JW, et al. Adult immunization schedule recommended by the Korean Society of Infectious Diseases, 2007. Infect Chemother 2008;40:1-13. https://doi.org/10.3947/ic.2008.40.1.1
  15. Keeffe EB. Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases. Trans Am Clin Climatol Assoc 2006;117:227-237.
  16. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-290. https://doi.org/10.1056/NEJM199801293380503
  17. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-205.
  18. Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007;357:1685-1694. https://doi.org/10.1056/NEJMoa070546
  19. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007;56:1080-1084.
  20. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009; 15(Suppl 6):S13-S24. https://doi.org/10.3350/kjhep.2009.15.S6.S13
  21. Jeong S, Yim HW, Bae SH, Lee WC. Changes of hepatitis B surface antigen seroprevalence in Korea, 1998-2005. Korean J Epidemiol 2008;30:119-127. https://doi.org/10.4178/kje.2008.30.1.119
  22. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539. https://doi.org/10.1002/hep.21513
  23. Lee KI, Park KS, Seo HJ, et al. Shifting in seroprevalence of HBsAg and anti-HCV during recent 10 years in adults resident in Daegu and Gyeongbuk Province. Korean J Gastroenterol 2011;58:82-87. https://doi.org/10.4166/kjg.2011.58.2.82
  24. Oh MK, Kim JS, Lee YB, Han JH. Seroprevalence of hepatitis B virus markers among adult in a Youngdong area of Kwangwon Province. J Korean Acad Fam Med 2000;21: 91-99.
  25. Kim CY. Prevention of viral hepatitis, type B, by vaccination with purified hepatitis B surface antigen. J Korean Med Sci 1976;22:1013-1025.
  26. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1-33; quiz CE31-34.
  27. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54:1-31.
  28. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-1102.
  29. Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998;27:100-106. https://doi.org/10.1086/514610
  30. Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007;166:813-818. https://doi.org/10.1007/s00431-006-0327-5
  31. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190:489-492.
  32. Del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997;15:1624-1630. https://doi.org/10.1016/S0264-410X(97)00080-7
  33. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103. https://doi.org/10.1111/j.1365-2893.2008.01056.x
  34. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010;116:147-159. https://doi.org/10.1097/AOG.0b013e3181e45951
  35. Pan C, Han GR, Zhao W, Jiang HX, Cao MK. A prospective open-label study to evaluate the efficacy, safety and tolerability of telbivudine (LdT) in HBeAg+ chronic hepatitis B (CHB) pregnant women. Hepatology 2010; 52(Suppl 1):500A.
  36. Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2:740-741.
  37. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002;99:1049-1052.
  38. Nordenfelt E, Dahlquist E. HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B. Scand J Infect Dis 1978;10:161-163. https://doi.org/10.3109/inf.1978.10.issue-3.01
  39. Steinberg SC, Alter HJ, Leventhal BG. The risk of hepatitis transmission to family contacts of leukemia patients. J Pediatr 1975;87:753-756. https://doi.org/10.1016/S0022-3476(75)80300-3
  40. Harpaz R, Von Seidlein L, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996;334:549-554. https://doi.org/10.1056/NEJM199602293340901
  41. Buster EH, van der Eijk AA, Schalm SW. Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions. Antiviral Res 2003;60: 79-85. https://doi.org/10.1016/j.antiviral.2003.08.014
  42. Alter HJ, Seeff LB, Kaplan PM, et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976;295:909-913. https://doi.org/10.1056/NEJM197610212951701
  43. Grady GF, Maxfield HK, Hildreth SW, et al. Eastern equine encephalitis in Massachusetts, 1957-1976: a prospective study centered upon analyses of mosquitoes. Am J Epidemiol 1978;107:170-178. https://doi.org/10.1093/oxfordjournals.aje.a112519
  44. Seeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978;88:285-293. https://doi.org/10.7326/0003-4819-88-3-285
  45. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR Recomm Rep 1991;40(RR-8):1-9.
  46. Gunson RN, Shouval D, Roggendorf M, et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003;27:213-230. https://doi.org/10.1016/S1386-6532(03)00087-8
  47. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin: Irish Hepatology Research Group. N Engl J Med 1999;340: 1228-1233. https://doi.org/10.1056/NEJM199904223401602
  48. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of communityacquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000;32:582-587. https://doi.org/10.1053/jhep.2000.9714
  49. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
  50. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914. https://doi.org/10.1002/hep.510290311
  51. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992;16:1109-1114. https://doi.org/10.1002/hep.1840160502
  52. Chung H, Kudo M, Kumada T, et al. Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. J Gastroenterol 2003; 38:877-879. https://doi.org/10.1007/s00535-003-1156-1
  53. De Carli G, Puro V, Ippolito G; Studio Italiano Rischio Occupazionale da HIV Group. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003;31(Suppl 2):S22-S27.
  54. Lee H, Cho YK, Kim HU, et al. Distribution of hepatitis C virus genotypes in Jeju Island. Korean J Hepatol 2008;14:28-35. https://doi.org/10.3350/kjhep.2008.14.1.28
  55. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J Infect Dis 1995;171: 768-775. https://doi.org/10.1093/infdis/171.4.768
  56. Vandelli C, Renzo F, Romanò L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004;99:855-859. https://doi.org/10.1111/j.1572-0241.2004.04150.x
  57. Chen CY, Lu CL, Huang YS, et al. Age is one of the risk factors in developing gallstone disease in Taiwan. Age Ageing 1998;27:437-441. https://doi.org/10.1093/ageing/27.4.437
  58. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002;36(5 Suppl 1):S106-S113.
  59. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880-1889. https://doi.org/10.1086/497701
  60. Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995;126:589-591. https://doi.org/10.1016/S0022-3476(95)70356-X
  61. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease: Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1-39.
  62. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321-332. https://doi.org/10.1016/S0140-6736(08)61116-2
  63. Kim NJ, Lee JS, Kim KA, et al. A case of acute hepatitis E. Korean J Hepatol 2002;8:312-316.
  64. Park HK, Woo BH, Jeong SH, et al. The seroprevalence of hepatitis E virus (HEV) infection in a Korean population: comparison of two commercial anti-HEV assays. Korean J Hepatol 2011;17(Suppl 3):S54.
  65. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895-903. https://doi.org/10.1056/NEJMoa061847
  66. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376:895-902. https://doi.org/10.1016/S0140-6736(10)61030-6
  67. U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 2001;50(RR-11):1-52.

Cited by

  1. Viral Hepatitis and Liver Cancer in Korea: an Epidemiological Perspective vol.14, pp.11, 2013, https://doi.org/10.7314/apjcp.2013.14.11.6227
  2. The Economic Burden of Hepatitis A, B, and C in South Korea vol.69, pp.1, 2012, https://doi.org/10.7883/yoken.jjid.2014.499
  3. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea vol.16, pp.4, 2018, https://doi.org/10.5217/ir.2018.00012
  4. B형 간염 예방접종 전후 연령별 B형 간염 표면항체 양성률에 대한 융합적 연구 vol.11, pp.1, 2020, https://doi.org/10.15207/jkcs.2020.11.1.077